The sale simplifies Clarivate's structure and reduces leverage, but the remaining business still shows a pro forma net loss. Monitor the Q3 2026 earnings for actual discontinued operations classification and any updated guidance on the continuing business's trajectory.
Price Chart
Executive Summary
Clarivate filed this 8-K/A to provide pro forma financials for the completed sale of its Life Sciences and Healthcare (LSH) business to an Altaris affiliate for $600 million total consideration. The sale closed on October 6, 2026, with Clarivate receiving approximately $488.4 million in net cash, a $75 million unsecured senior note, and $25 million in deferred cash. Proceeds were used to pay down debt, reducing long-term debt from $4.21 billion to $3.63 billion on a pro forma basis, while the company's continuing operations show a pro forma net loss of $79.6 million for the first half of 2026.
Key Facts
- Clarivate completed the sale of its Life Sciences and Healthcare business on October 6, 2026 for total consideration of $600 million.
- Consideration comprised approximately $488.4 million net cash at close, a $75 million unsecured senior note, and $25 million deferred cash payable by January 31, 2028.
- Pro forma long-term debt reduced from $4.21 billion to $3.63 billion, with $575 million of debt repaid using sale proceeds and company cash.
- Pro forma continuing operations revenue was $990.8 million for H1 2026 (down from $1.17 billion historical) and $2.07 billion for FY2025 (down from $2.46 billion historical).
- Pro forma continuing operations net loss was $79.6 million for H1 2026 and $172.1 million for FY2025.
- The sale represents a strategic shift and is classified as discontinued operations; the gain/loss on sale is not expected to be material.
- Approximately $20 million of non-recurring transaction costs were incurred and will be classified within discontinued operations.
Financial Impact
Sale proceeds of $600 million used to reduce debt by $575 million; continuing operations revenue declines ~15% but removes loss-making LSH segment, improving operating income from -$170M to +$41.4M on a pro forma H1 2026 basis.
Risk Factors
- Pro forma financials are unaudited and may differ materially from actual results.
- Continuing operations remain unprofitable on a pro forma basis, with net losses of $79.6M (H1 2026) and $172.1M (FY2025).
- The $75 million unsecured senior note and $25 million deferred cash consideration are subject to counterparty risk and TSA completion.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K/A Filing (Primary) | 0001764046-26-000122 |
| Document: clvt-20261006.htm | 0001764046-26-000122 |
| Document: 0001764046-26-000122-index-headers.html | 0001764046-26-000122 |
| Document: 0001764046-26-000122-index.html | 0001764046-26-000122 |
| Document: 0001764046-26-000122.txt | 0001764046-26-000122 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 8-K/A | $1.61 | awaiting T+20 | — | $1.87 (+16.15%) |
Oct 6, 2026 20d ago | 8-K | $1.47 | awaiting T+20 | — | $1.87 (+27.21%) |
Sep 24, 2026 4w ago | 8-K | $1.84 $1.85 | ▲ +0.54% | ▲ +0.96% | $1.87 (+1.63%) |
Sep 22, 2026 4w ago | Press Release | $1.89 $1.78 | ▼ −5.82% | ▼ −5.26% | $1.87 (−1.06%) |
Sep 17, 2026 5w ago | Press Release | $1.90 $1.74 | ▼ −8.42% | ▼ −9.88% | $1.87 (−1.58%) |
Aug 10, 2026 11w ago | Insider Cluster | $1.91 $1.91 | · 0.00% | ▲ +1.06% | $1.87 (−2.09%) |
Aug 3, 2026 12w ago | 144 | $1.97 $2.04 | ▼ −3.55% | ▼ −4.79% | $1.87 (+5.08%) |
Jul 6, 2026 16w ago | 8-K | $2.51 $1.94 | ▼ −22.71% | ▼ −24.04% | $1.87 (−25.50%) |
Jul 6, 2026 16w ago | 8-K | $2.44 $1.98 | ▼ −18.85% | ▼ −18.29% | $1.87 (−23.36%) |
Jun 8, 2026 20w ago | 8-K | $2.38 $2.51 | ▲ +5.46% | ▲ +4.02% | $1.87 (−21.43%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers